1. Home
  2. GAUZ vs MGNX Comparison

GAUZ vs MGNX Comparison

Compare GAUZ & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Gauzy Ltd. Ordinary Shares

GAUZ

Gauzy Ltd. Ordinary Shares

N/A

Current Price

$1.16

Market Cap

102.0M

Sector

Miscellaneous

ML Signal

N/A

Logo MacroGenics Inc.

MGNX

MacroGenics Inc.

N/A

Current Price

$1.61

Market Cap

94.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
GAUZ
MGNX
Founded
2009
2000
Country
Israel
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Miscellaneous
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
102.0M
94.9M
IPO Year
2024
2013

Fundamental Metrics

Financial Performance
Metric
GAUZ
MGNX
Price
$1.16
$1.61
Analyst Decision
Strong Buy
Hold
Analyst Count
2
5
Target Price
$11.50
$3.20
AVG Volume (30 Days)
294.3K
1.4M
Earning Date
03-11-2026
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$96,810,000.00
$127,626,000.00
Revenue This Year
$22.59
N/A
Revenue Next Year
$47.83
N/A
P/E Ratio
N/A
N/A
Revenue Growth
7.87
N/A
52 Week Low
$0.95
$0.99
52 Week High
$13.00
$3.60

Technical Indicators

Market Signals
Indicator
GAUZ
MGNX
Relative Strength Index (RSI) 26.52 59.83
Support Level $0.95 $1.32
Resistance Level $1.32 $1.45
Average True Range (ATR) 0.29 0.10
MACD 0.06 0.02
Stochastic Oscillator 11.80 84.85

Price Performance

Historical Comparison
GAUZ
MGNX

About GAUZ Gauzy Ltd. Ordinary Shares

Gauzy Ltd is a fully integrated light and vision control company. Its products include suspended particle device and liquid crystal materials for smart glass applications and AI-powered driver assistance systems, or ADAS, solutions including camera monitoring systems. The company's operating segments are Architecture, Automotive, Safety tech, and Aeronautics. Maximum revenue is generated from its Safety tech segment, which focuses on sales of driver assistance systems for buses, coaches, recreational vehicles, and specific vehicles, such as camera and motion sensor systems, smart mirrors, and safety doors. Geographically, it derives maximum revenue from other European countries (excluding France), followed by the United States, France, Asia, Israel, and other regions.

About MGNX MacroGenics Inc.

Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.

Share on Social Networks: